Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Completed · Phase 1
Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
In brief
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or RP2D of the orally administered PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162. This combination will be explored in patients with EGFR mutant NSCLC which has progressed on EGFR inhibitors and triple negative breast cancer, as well as pancreatic cancer, colorectal cancer, malignant melanoma, NSCLC, and other advanced solid tumors with KRAS, NRAS, and/or BRAF mutations. Dose escalation will be guided by a Bayesian logistic regression model with overdose control. At MTD or RP2D, two expansion arms will be opened in order to further assess safety and preliminary anti-tumor activity of the combination of BEZ235 and MEK162. Study drugs will be administered orally on a continuous schedule, MEK162 bid and BEZ235 qd, a treatment cycle is defined as 28 days.
Key facts
- Study ID
- NCT01337765
- Run by
- Pfizer
- People needed
- 29
- Starts
- 2011-07-08
- Expected to finish
- 2013-03-22
- Last updated by the study team
- 2020-10-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- histologically/cytologically confirmed, advanced non resectable solid tumors
- Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0
You may not qualify if…
- Patients with primary CNS tumor or CNS tumor involvement
- Diabetes mellitus - Unacceptable ocular/retinal conditions
- Other protocol-defined inclusion/exclusion criteria may apply
Where it is running
- Massachusetts General Hospital Mass General 2 — Boston, Massachusetts, United States
- University of Texas/MD Anderson Cancer Center MD Anderson PSC — Houston, Texas, United States
- Pfizer Investigative Site — Parkville, Victoria, Australia
- Pfizer Investigative Site — Toronto, Ontario, Canada
- Pfizer Investigative Site — Villejuif, France
- Pfizer Investigative Site — Barcelona, Catalonia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.